Catalyst Wire Dossier Catalyst Wire Dossier

90Y-ibritumomab tiuxetan

ibritumomab tiuxetan
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for 90Y-ibritumomab tiuxetan, covering 2010-07-08 to 2010-07-08. Get the full timeline:

Most recent: Clinical Trial Update: 90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma [Phase 2]

See pricing